EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Designed Peptide Coacervates for Extracellular Antibody Targeting

Nofar Berman iD, Omer Grotto, Limor Nahary, Itai Benhar iD, Ayala Lampel iD

Small · 09.11.2026

DOI: 10.1002/smll.76628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 09.11.2026. Verfasst von Nofar Berman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Israel Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic antibodies have transformed the treatment of cancer and immune‐related diseases. However, improving their stability, protection from degradation, and efficient interaction with target cells remain major challenges. Peptide coacervates, formed by liquid‐liquid phase separation (LLPS), are emerging supramolecular assemblies that offer membraneless microenvironments for encapsulation and enrichment of polar macromolecules and thus are especially attractive for delivery applications. Here, we design minimalistic coacervates formed by oppositely charged peptides through LLPS as a functional biomaterial platform for efficient sequestration and extracellular targeting of monoclonal antibodies (mAbs). We use Rituximab (RIT), a human IgG1 mAb targeting CD20 on B cells, widely used in the treatment of B cell malignancies and autoimmune diseases, as a therapeutic mAb model. We show that the coacervates remain stable under physiologically relevant conditions, including serum‐containing media and acidic pH, and that they can efficiently encapsulate RIT. Encapsulation within the coacervates enhances antibody‐cell interactions and provides partial protection against enzymatic proteolysis, while coacervates maintain low cytotoxicity. Importantly, we demonstrate that the antibody biological activity is preserved by retaining complement‐dependent cytotoxicity against CD20‐expressing cells. Thus, our findings suggest that encapsulation within the peptide coacervates provides a promising strategy for improving stability, functionality, and extracellular delivery of therapeutic antibodies.

Schlagwörter

Stichwörter der Autor:innen

antibody deliverycoacervatescondensatesextracellular deliveryliquid‐liquid phase separationpeptidesrituximab

Autor:innen und Institutionen

  • Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel.
  • Center For Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, Israel.
  • Center For Physics and Chemistry of Living Systems, Tel Aviv University, Tel Aviv, Israel.
  • Division Polymer Biomaterials Science, Leibniz Institute of Polymer Research Dresden, Dresden, Germany.

ORCID-Profile: Nofar Berman, Itai Benhar, Ayala Lampel

Förderung

  • European Research Council
  • Israel Science Foundation

Zitieren

APA

Berman, N., Grotto, O., Nahary, L., Benhar, I., & Lampel, A. (2026). Designed Peptide Coacervates for Extracellular Antibody Targeting. Small. https://doi.org/10.1002/smll.76628

Vancouver

Berman N, Grotto O, Nahary L, Benhar I, Lampel A. Designed Peptide Coacervates for Extracellular Antibody Targeting. Small. 2026. doi:10.1002/smll.76628

BibTeX
@article{Berman2026,
  author = {Berman, Nofar and Grotto, Omer and Nahary, Limor and Benhar, Itai and Lampel, Ayala},
  title = {Designed Peptide Coacervates for Extracellular Antibody Targeting},
  journal = {Small},
  year = {2026},
  doi = {10.1002/smll.76628}
}
Kostenlos starten →